Abstracts Archive - Page 906 of 2607 - ACR Meeting Abstracts

Abstract Number: 1044 • ACR Convergence 2020
Ocular Manifestations in Inflammatory Bowel Disease. Study of 1442 Patients from a Single Referral Center
Lara Sanchez-Bilbao¹, David Martinez-Lopez², Inigo Gonzalez-Mazon³, Maria José García-García⁴, Montserrat Rivero-Tirado⁴, Beatriz Castro⁴, Javier Crespo⁴, Miguel Ángel González-Gay⁵ and Ricardo Blanco¹, ¹Hospital Universitario Marques de Valdecilla, Santander, Spain, ²Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ³Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Inflammatory bowel disease (IBD), which includes Crohn's disease (CD), and Ulcerative colitis (UC) are related to Spondyloarthritis (SpA). Ocular manifestations (OM) are well-stablished in…
Abstract Number: 1045 • ACR Convergence 2020
Biological therapy in atypical optic neuritis refractory to conventional treatment. A multicenter study with 19 patients.
Inigo Gonzalez-Mazon¹, Alba Herrero Morant², Lara Sanchez-Bilbao², David Martinez-Lopez³, Vanesa Calvo-Río⁴, Carmen Alvarez-Reguera², Santos Castañeda⁵, Esther Francisca Vicente-Rabaneda⁶, Rosalia Demetrio-Pablo², Ana Urruticoechea-Arana⁷, J. L. García-Serrano⁸, J. L. Callejas-Rubio⁸, Norberto Ortego⁸, José Luis Martín-Varillas⁹, Olga Maiz Alonso¹⁰, Ana Blanco¹¹, Francisco Javier Narváez¹², Susana Romero-Yuste¹³, Iñigo Rúa-Figueroa¹⁴, Paula Estrada¹⁵, Julio Sanchez¹⁶, Miguel Ángel González-Gay¹⁷ and Ricardo Blanco², ¹Hospital Universitario Marques de Valdecilla, Bezana, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁴H.U. Marques de Valdecilla, Santander, Spain, ⁵Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ⁶Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ⁷HOSPITAL CAN MISSES EIVISSA, Ibiza, Spain, ⁸Hospital Universitario San Cecilio, Granada, Spain, ⁹Hospital Sierrallana, Torrelavega, Spain, ¹⁰Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, ¹¹Hospital Universitario Donostia, San Sebastian, Spain, ¹²Hospital Bellvitge, BARCELONA, Spain, ¹³H Pontevedra, Coruna, Spain, ¹⁴Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, ¹⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶Hospital 12 Octubre, Madrid, Spain, ¹⁷Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Optic Neuritis (ON) is an inflammation of the optic nerve. Its most common presentation is demyelinating typical ON. Atypical ON is rare, severe, non-demyelinating…
Abstract Number: 1046 • ACR Convergence 2020
Risk Factors Associated with Interstitial Lung Disease in Patients with RA: Findings from a Retrospective Healthcare Database Analysis
Joe Zhuo¹, Qisu Zhang², Keith Knapp³, Yuexi Wang⁴, Cynthia Gutierrez⁴, Ding He⁴, Lin Xie⁴, Sonie Lama¹ and Gary Craig⁵, ¹Bristol-Myers Squibb Company, Princeton, NJ, ²STATinMED Research (at time of analysis), Ann Arbor, MI, ³Discus Analytics LLC, Spokane, WA, ⁴STATinMED Research, Ann Arbor, MI, ⁵Arthritis Northwest, PLLC, Spokane, WA
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of RA and is associated with increased morbidity and mortality.1 Previous studies have shown variability in…
Abstract Number: 1047 • ACR Convergence 2020
Prospective Analysis of a Cohort of Patients with Interstitial Lung Disease Associated with Connective Tissue Disease and Their Response to Immunosuppression with Mycophenolate Mofetil and Rituximab
Yan Li¹, Hassan Baig², Carlos Rojas², Justin Stowell², Elizabeth Lesser², Shalmali Borkar², Andy Abril¹ and Isabel Mira-Avendano¹, ¹Mayo Clinic, Ponte Vedra Beach, FL, ²Mayo Clinic, Jacksonville, FL
Background/Purpose: Connective tissue diseases (CTDs) are commonly identified causes for interstitial lung disease (ILD). Compared with idiopathic interstitial pneumonias, patients with CTD-ILD and interstitial pneumonia…
Abstract Number: 1048 • ACR Convergence 2020
Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib
Eric Matteson¹, Oliver Distler², Jörg HW Distler³, Masataka Kuwana⁴, Janet Pope⁵, James Seibold⁶, Alexandra James⁷, Rozsa Schlenker-Herceg⁸, Klaus Rohr⁷ and Kevin Flaherty⁹, ¹Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, MN, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ³University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan, ⁵Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁶Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, SC, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ⁹Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: In the randomized placebo-controlled INBUILD trial in patients with chronic fibrosing ILDs with a progressive phenotype, nintedanib reduced the rate of decline in forced…
Abstract Number: 1049 • ACR Convergence 2020
Effects of Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern
Paul Dellaripa¹, Martin Aringer², Anna Maria Hoffmann-Vold³, Clive Kelly⁴, Shikha Mittoo⁵, Alexandra James⁶, Klaus Rohr⁶, Susanne Stowasser⁶ and Yoshikazu Inoue⁷, ¹Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle upon Tyne, United Kingdom, ⁵University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁷Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan, Sakai City, Osaka, Japan
Background/Purpose: In the INBUILD trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks compared with placebo in patients with…
Abstract Number: 1050 • ACR Convergence 2020
Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center
Belén Atienza-Mateo¹, Sara Remuzgo-Martínez², Diana Prieto-Peña¹, Víctor Manuel Mora Cuesta³, David Iturbe-Fernández³, Sonia Fernández Rozas¹, Alfonso Corrales¹, José Manuel Cifrián² and Miguel Ángel González-Gay⁴, ¹Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL, Santander, Spain, ³Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: The presence of interstitial lung disease (ILD) in patients with autoimmune diseases (AD)s influences significantly on their morbidity and mortality [1]. Different treatment strategies…
Abstract Number: 1051 • ACR Convergence 2020
Rituximab for Interstitial Pneumonia with Autoimmune Features at Two Academic Medical Centers
Kristin D'Silva¹, Iazsmin Bauer Ventura², Marcy Bolster³, Flavia Castelino⁴, Amita Sharma¹, Brent Little¹, Ayodeji Adegunsoye², Mary Strek², Sydney Montesi¹ and Hyon Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²University of Chicago, Chicago, IL, ³Massachusetts General Hospital, Concord, MA, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: Many patients with interstitial lung disease (ILD) have autoimmune features without a distinct rheumatic disease and are thus designated as having interstitial pneumonia with…
Abstract Number: 1052 • ACR Convergence 2020
Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska
Joanna Marco¹ and Elizabeth Ferucci², ¹University of Washington, Seattle, WA, ²Alaska Native Tribal Health Consortium, Anchorage, AK
Background/Purpose: Many connective tissue diseases are known to cause interstitial lung disease (ILD). American Indian/Alaska Native (AI/AN) populations have higher prevalence and severity of a…
Abstract Number: 1053 • ACR Convergence 2020
Efficacy of Rituximab for Connective Tissue Disease (CTD) Associated Interstitial Lung Disease (ILD) : A Single Center Study of 47 Patients- Extension Study
Ahmad Qurie¹, Smita Maruvada¹, Sarwat Umer¹, Jerry Mclarty² and Samina Hayat¹, ¹LSU Shreveport, Shreveport, LA, ²LSU Shreveport, Shreveport
Background/Purpose: Interstitial lung disease (ILD) is a fatal complication associated with connective tissue diseases (CTDs), often resulting in substantial morbidity and mortality. Despite numerous advances…
Abstract Number: 1054 • ACR Convergence 2020
Treatment with Certolizumab Pegol in Refractory Uveitis Secondary to Inmune-Mediated Inflammatory Diseases. Multicenter Study of 39 Patients
José Luis Martín-Varillas¹, Vanesa Calvo-Río², Lara Sanchez-Bilbao², Inigo Gonzalez-Mazon³, Ignacio Torre⁴, Alvaro García Martos⁵, Amalia Sánchez Andrade⁶, Angel García Aparicio⁷, Juan Ramón De dios⁸, Ana Urriticoechea⁹, Olga Maiz Alonso¹⁰, Raul Veroz¹¹, Andrea García Valle¹², Sergio Rodriguez Montero¹³, Roberto Miguelez¹⁴, Vega Jovani¹⁵, Marisa Hernandez Garfella¹⁶, Arantxa Conesa¹⁷, Olga Martinez Gonzalez¹⁸, Paula Rubio Muñoz¹⁹, Eva Peña Sainz-Pardo²⁰, Miguel Ángel González-Gay²¹ and Ricardo Blanco², ¹Hospital Sierrallana, Torrelavega, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁴Hospital Basurto, Bilbao, Spain, ⁵Hospital del Tajo, Madrid, Spain, ⁶H. Lucus Augusti, Lugo, Spain, ⁷H. Mostoles, Madrid, Spain, ⁸H. Alava, Alava, Spain, ⁹Can Misses, Ibiza, Spain, ¹⁰Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, ¹¹H. Mérida, Mérida, Spain, ¹²H. Palencia, Palencia, Spain, ¹³H. Virgen de Valme, Sevilla, Spain, ¹⁴Toledo, Toledo, Spain, ¹⁵H. Alicante, Alicante, Spain, ¹⁶H. Valencia, Valencia, Spain, ¹⁷H. Castellón, Castellón, ¹⁸H. Salamanca, Salamanca, ¹⁹H. Esperit Sant, Barcelona, Spain, ²⁰H. 12 de Octubre, Madrid, Spain, ²¹Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Infliximab and adalimumab therapy has significantly improved the prognosis of patients with non-infectious refractory uveitis. However, there is not enough evidence for the use…
Abstract Number: 1055 • ACR Convergence 2020
Myositis and Systemic Sclerosis Spectrum IPAF Patients Are More Likely to Respond Favorably to Immunosuppression
Erin Wilfong¹, Gabriel Schroeder¹, April Barnado¹, Steven Lord¹, Narender Annapureddy¹, Rosemarie Dudenhofer¹ and Leslie J. Crofford¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Classification criteria for interstitial pneumonia with autoimmune features (IPAF) were introduced in 2015 to identify interstitial lung disease (ILD) patients who might benefit from…
Abstract Number: 1056 • ACR Convergence 2020
Descriptive Data Analysis of Patients with Anti Jo1 Syndrome (AJS) and Lung Involvement
Mohamed Alalwani¹, Bassam Alhaddad², Basem Zraik³, Christopher O'Rourke³, Ruchi Yadav³, Ali Askari¹, Charles Malemud¹ and Soumya Chatterjee⁴, ¹Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, OH, ²MetroHealth Medical Center, Westlake, OH, ³Cleveland Clinic, Cleveland, OH, ⁴Cleveland Clinic, Richmond Heights, OH
Background/Purpose: To evaluate the patterns, severity and, prognostic parameters of interstitial lung disease (ILD) in Anti Jo1 Syndrome (AJS).Methods: We identified 51 anti-Jo-1 patients with…
Abstract Number: 1057 • ACR Convergence 2020
Earlier Cancer Diagnosis After Idiopathic Inflammatory Myopathy Onset Is Associated with Improved Long Term Survival – Results from Four European Cohorts
Alexander Oldroyd¹, Paul New², Janine Lamb¹, William Ollier¹, Robert Cooper², Kuberacka Mariampillai³, Olivier Benveniste³, Jiří Vencovský⁴, Heřman Mann⁵, Zoltan Griger⁶, Melinda Nagy-Vincze⁶, Katalin Dankó⁶ and Hector Chinoy⁷, ¹University of Manchester, Manchester, United Kingdom, ²University of Liverpool, Liverpool, United Kingdom, ³Sorbonne Université, Paris, France, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶University of Debrecen, Debrecen, Hungary, ⁷The University of Manchester, Manchester, United Kingdom
Background/Purpose: The idiopathic inflammatory myopathies (IIMs) are strongly associated with the development of clinically detectable cancer. Cancer screening has therefore been advocated in newly diagnosed…
Abstract Number: 1058 • ACR Convergence 2020
The Relationship of Different Muscle Enzymes in Adult Myositis Patients
Rohit Aggarwal¹ and Tanya Chandra², ¹University of Pittsburgh, Pittsburgh, PA, ²University of Connecticut, HARTFORD, CT
Background/Purpose: Muscle enzymes are a core set measure (CSM) in clinical trials. The 2016 ACR/EULAR myositis response criteria and the IMACS definition of improvement recommend…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].